Clinical trials: Prostate Cancer Stage
Prostate Cancer
Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer
Background: Flutamide is an approved drug for prostate cancer that blocks the effects of testosterone on prostate cancer cells and may slow the progression of the disease.
- Trial name
- NCT00450463
- Testing
- Sargramostim (GM-CSF, Leukine), Flutamide (Eulexin), PROSTVAC-F/ TRICOM
- Where
- 3 sites in United States
- Volunteers
- 64 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)
This research study is comparing two different combinations of androgen deprivation therapy (ADT) used together with radiation as a treatment for rising PSA after radical prostatectomy (prostate cancer).
- Trial name
- NCT03141671
- Testing
- GnRH, Bicalutamide, Salvage radiation
- Where
- 8 sites in United States
- Volunteers
- 345 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate Cancer
Selenium in Treating Patients Who Are Undergoing Brachytherapy for Stage I or Stage II Prostate Cancer
RATIONALE: The use of nutritional supplements, such as selenium, may stop prostate cancer from growing. Internal radiation, such as brachytherapy, uses radioactive material placed directly into or near a tumor to kill tumor…
- Trial name
- NCT00217516
- Testing
- selenium
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Roswell Park Cancer Institute
Prostatic Neoplasms, Castration-Resistant
64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
The aim of this study is to determine the safety and efficacy of 67Cu-SAR-bisPSMA in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
- Trial name
- SECuRE (NCT04868604)
- Testing
- 64Cu-SAR-bisPSMA, 67Cu-SAR-bisPSMA
- Where
- 7 sites in United States
- Volunteers
- 54 people
- Sponsor
- Clarity Pharmaceuticals Ltd
Blood Loss, Surgical, Prostate Cancer
Safety Study of Hemospan® in Prostatectomy Patients
This is a progressive dose escalation study designed to evaluate the safety of Hemospan compared to a standard crystalloid solution (Ringer's lactate) in elective surgery patients undergoing total prostatectomy procedures with…
- Conditions
- Blood Loss, Surgical, Prostate Cancer, Surgery
- Trial name
- NCT00425334
- Testing
- Hemospan (MP4OX), Ringer's lactate
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Sangart
Prostate Cancer
To Evaluate the Effect of MCS® in Prostate Cancer Prevention
To evaluate the effect of MCS® compared with placebo in reducing the risk of biopsy-detectable prostate cancer in high-risk subjects after 104 weeks (24 months) of treatment.
- Trial name
- MCS-8 (NCT02042807)
- Testing
- MCS®
- Where
- Taiwan
- Volunteers
- 702 people
- Sponsor
- Health Ever Bio-Tech Co., Ltd.
Prostate Cancer
BMS-247550 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BMS-247550 in treating patients who have prostate…
- Trial name
- NCT00016393
- Testing
- ixabepilone
- Where
- 28 sites in United States
- Sponsor
- SWOG Cancer Research Network
Advanced Cancers
End of Life Treatment Preferences of Latino Medicare Beneficiaries With Cancer
Objectives: The primary objective of the research project is to investigate how declining health status influences the end-of-life (EOL) treatment preferences in Latino Medicare beneficiaries with cancer and to examine if and how…
- Trial name
- NCT01389830
- Testing
- Telephone Survey
- Where
- United States
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer, Prostate Cancer Stage
Comparison of Multiparametric Prostate MRI and Ga-68 PSMA PET Imaging in Prostate Cancer Staging
In this study, it is aimed to compare the lesion location, lesion size, local and distant metastases detection rates of Ga68 PSMA PET and Multiparametric Prostate MR imaging tests used in staging in patients diagnosed with…
- Trial name
- NCT05427864
- Testing
- Multiparametric Prostate MRI
- Where
- Turkey (Türkiye)
- Volunteers
- 47 people
- Sponsor
- Gulhane Training and Research Hospital
Neoplasms
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
Determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of VIP152 (BAY 1251152) as monotherapy or in combination in patients with solid tumors and aggressive…
- Trial name
- NCT02635672
- Testing
- VIP152 (BAY 1251152), VIP152 (BAY 1251152) 30 mg, Keytruda
- Where
- 16 sites in United States, Chile and 1 more
- Volunteers
- 110 people
- Sponsor
- Vincerx Pharma, Inc.
Prostate Cancer
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
This is a Phase 3 randomized, double blind, placebo controlled study of tasquinimod in asymptomatic to mildly symptomatic patients with metastatic CRPC to confirm the effect of tasquinimod on delaying disease progression compared…
- Trial name
- NCT01234311
- Testing
- tasquinimod
- Where
- 204 sites in United States, Argentina and 35 more
- Volunteers
- 1,245 people
- Sponsor
- Active Biotech AB
Hematologic Neoplasms, Prostatic Neoplasms
Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate Cancer
The purpose of this study is to determine the highest feasible dose (HFD) of intravenous (IV) APR-246 when given to patients with refractory hematologic malignancies or prostate carcinoma.
- Trial name
- NCT00900614
- Testing
- APR-246
- Where
- 6 sites in Sweden
- Volunteers
- 36 people
- Sponsor
- Aprea Therapeutics
Metastatic Castration-resistant Prostate Cancer
[177Lu]Ludotadipep Treatment in Patients With Metastatic Castration-resistant Prostate Cancer.
The study aims to evaluate the stability and efficacy after administration of [177Lu]Ludotadipep in patients with metastatic castration resistant prostate cancer (mCRPC), with dose-escalation applied to determine the appropriate…
- Trial name
- NCT04509557
- Testing
- [177Lu]Ludotadipep
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- FutureChem
Prostate Cancer Metastatic
Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)
PEACE-6 Poor Responders is an international, multicenter, open-label, controlled, randomized, phase III trial to evaluate the efficacy and safety of 177Lu-PSMA-617 when administered on top of the ongoing standard systemic…
- Trial name
- NCT06496581
- Testing
- 177Lu-PMSA-617, Standard of Care
- Where
- 25 sites in France
- Volunteers
- 500 people
- Sponsor
- UNICANCER
Brain Tumors, Gastric Cancer
S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian Cancer
RATIONALE: Vaccines made from a peptide may make the body build an immune response to kill cancer cells. PURPOSE: This phase I trial is studying two different vaccines to treat patients who have gastric, prostate, or ovarian…
- Conditions
- Brain Tumors, Gastric Cancer, Ovarian Cancer, Prostate Cancer
- Trial name
- NCT00023634
- Testing
- KLH, GMCSF
- Where
- 13 sites in United States
- Volunteers
- 14 people
- Sponsor
- SWOG Cancer Research Network
Prostate Cancer
Biomarker Monitoring of Prostate Cancer Patients With RSI MRI (ProsRSI)
Adult male patients with high-risk, localized prostate cancer and planning to undergo radiation therapy (RT) with androgen deprivation therapy (ADT) will undergo an advanced Magnetic Resonance Imaging (MRI) examination called…
- Trial name
- ProsRSI (NCT04349501)
- Testing
- Restriction Spectrum Imaging Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of California, San Diego
Prostate Cancer
Short Course ADT for High Risk Low/Intermediate Risk ARTERA Prostate Cancer
For this study, high risk prostate cancer patients with lower risk ARTERA scores will be treated with 6 months of Androgen Deprivation Therapy (ADT) in conjunction with dose escalated radiotherapy to the prostate and nodes.
- Trial name
- NCT07801664
- Testing
- Androgen Deprivation Therapy (ADT), Radiotherapy
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- NYU Langone Health
Prostate Cancer
Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC
This clinical trial studies the effect of radium-223 when added to sipuleucel-T for treating castrate-resistant prostate cancer that has spread to the bone.
- Trial name
- NCT02463799
- Testing
- Radium-223, Sipuleucel-T
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
Telmisartan in Prostate Cancer
The goal of this clinical trial is to learn about the tolerability of telmisartan in patients with prostate cancer, but evidence for treatment efficacy will also be gathered.
- Trial name
- NCT06168487
- Testing
- Telmisartan, Standard of Care Regimen
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Tyler J Curiel
Advanced Prostate Adenocarcinoma
To Determine an Effective Dose of VERU-100 for the Treatment of Advanced Prostate Cancer
To determine an effective dose of VERU-100 for the treatment of advanced prostate cancer by assessing its effect on testosterone levels by Day 28 and maintenance through Day 91.
- Trial name
- VERU-100 (NCT04843319)
- Testing
- VERU-100
- Where
- 11 sites in United States
- Volunteers
- 24 people
- Sponsor
- Veru Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.